Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 1
2005 1
2006 1
2008 2
2009 3
2010 3
2011 4
2012 4
2013 4
2014 6
2015 5
2016 8
2017 3
2018 14
2019 16
2020 28
2021 20
2022 12
2023 12
2024 7
2025 11
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Results by year

Filters applied: . Clear all
Page 1
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
Marston NA, Bohula EA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Murphy SA, Walsh E, Liu L, Verma S, Sattar N, Nicholls SJ, Lopez-Sendon J, Gouni-Berthold I, Tokgozoglu L, Blankstein R, Cyrille M, da Silva Lima GP, Giugliano RP, Sabatine MS; VESALIUS-CV Investigators. Marston NA, et al. JAMA. 2026 Apr 28;335(16):1400-1407. doi: 10.1001/jama.2026.3277. JAMA. 2026. PMID: 41903215 Clinical Trial.
IMPORTANCE: Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors for cardiovascular event reduction has largely been reserved for patients with significant atherosclerosis. ...CONCLUS …
IMPORTANCE: Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type …
Migraine and cardiovascular disease: what cardiologists should know.
Kalkman DN, Couturier EGM, El Bouziani A, Dahdal J, Neefs J, Woudstra J, Vogel B, Trabattoni D, MaassenVanDenBrink A, Mehran R, de Winter RJ, Appelman Y. Kalkman DN, et al. Among authors: trabattoni d. Eur Heart J. 2023 Aug 7;44(30):2815-2828. doi: 10.1093/eurheartj/ehad363. Eur Heart J. 2023. PMID: 37345664 Free article.
Robust evidence exists on the association between migraine with aura and increased incidence of cardiovascular disease (CVD), in particular ischaemic stroke. People with migraine with aura have an increased risk of atrial fibrillation, myocardial infarction, and cardiov …
Robust evidence exists on the association between migraine with aura and increased incidence of cardiovascular disease (CVD), in part …
Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis.
Paradies V, Masiero G, Rubboli A, Van Beusekom HMM, Costa F, Capranzano P, Degrauwe S, Gorog DA, Jorge CM, Buchanan GL, Alasnag M, Trabattoni D, Fraccaro C, Sibbing D, Dudek D, Vilahur G, Chieffo A, Mehran R, Capodanno D, Barbato E, Siller-Matula JM. Paradies V, et al. Among authors: trabattoni d. Eur Heart J. 2025 Jul 21;46(28):2730-2741. doi: 10.1093/eurheartj/ehaf352. Eur Heart J. 2025. PMID: 40390370 Free article.
The current clinical consensus statement highlights the need for an increased awareness of sex-specific risks and biases in ACS management, with a focus on sex-specific bleeding mitigation strategies, antithrombotic management in special conditions (e.g., myocardial infarction wi …
The current clinical consensus statement highlights the need for an increased awareness of sex-specific risks and biases in ACS management, …
Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis.
Paradies V, Masiero G, Rubboli A, Van Beusekom HMM, Costa F, Capranzano P, Degrauwe S, Gorog DA, Jorge CM, Buchanan GL, Alasnag M, Trabattoni D, Fraccaro C, Sibbing D, Dudek D, Vilahur G, Chieffo A, Mehran R, Capodanno D, Barbato E, Siller-Matula JM. Paradies V, et al. Among authors: trabattoni d. EuroIntervention. 2025 Jun 16;21(12):e655-e667. doi: 10.4244/EIJ-D-24-00876. EuroIntervention. 2025. PMID: 40388110 Free PMC article.
The current clinical consensus statement highlights the need for an increased awareness of sex-specific risks and biases in ACS management, with a focus on sex-specific bleeding mitigation strategies, antithrombotic management in special conditions (e.g., myocardial infarction wi …
The current clinical consensus statement highlights the need for an increased awareness of sex-specific risks and biases in ACS management, …
15-Year Outcomes of PFO Closure in Patients With Cryptogenic Embolism: Insights From the PROLONG Registry.
Gaspardone C, Trabattoni D, d'Atri DO, Morosato M, Costa P, Fraccaro C, Donti A, Saia F, Toscano E, Scalise F, Cucco A, Patti G, Nerla R, Castriota F, Trani C, Improta R, Mancone M, Sardella G, Musto C, Paciaroni M, Morciano DA, Ricchetti G, Zaccaria L, Beneduce A, Barone G, Salerno A, Vella CS, Montorfano M, Pappone C, Colombo A, Maisano F, Burzotta F, Tarantini G, Margonato A, Gaspardone A, Godino C. Gaspardone C, et al. Among authors: trabattoni d. JACC Cardiovasc Interv. 2025 Jun 23;18(12):1526-1537. doi: 10.1016/j.jcin.2025.04.041. JACC Cardiovasc Interv. 2025. PMID: 40562467 Free article.
Women's heart centres: a clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI), the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the Heart Failure Association (HFA), and the Association for Acute CardioVascular Care (ACVC) of the ESC.
Grapsa J, Almeida AG, Sambola A, Vitale C, Appelman Y, Shivalkar B, Anderson LJ, Trabattoni D, Perez RV, Rakisheva A, Kaluzna-Oleksy M, Halvorsen S, Gevaert S, Adamo M, Price S, Gimelli A, Cosyns B, Delgado V, Chieffo A, Moura B, Shaw L, Alasnag M, Mehran R, Mulvagh SL, Mamas MA, Gulati M. Grapsa J, et al. Among authors: trabattoni d. Eur Heart J. 2026 May 26:ehag350. doi: 10.1093/eurheartj/ehag350. Online ahead of print. Eur Heart J. 2026. PMID: 42189053 Free article.
Cardiovascular disease is the leading cause of death in women, yet significant disparities persist in diagnosis, treatment, and research representation. ...Establishing WHC offers a structured approach to reduce inequities and strengthen cardiovascular care for wome …
Cardiovascular disease is the leading cause of death in women, yet significant disparities persist in diagnosis, treatment, and resea …
Diagnostic Accuracy of Dynamic Stress Myocardial CT Perfusion Compared with Invasive Physiology in Patients with Stents: The Advantage 2 Study.
Andreini D, Mushtaq S, Trabattoni D, Conte E, Sonck J, Lorusso G, Galli S, Monizzi G, Belmonte M, Grancini L, Teruzzi G, Troiano S, Gili S, Montorsi P, Olivares P, Mallia V, Marchetti D, Schillaci M, Gallinoro E, Paolisso P, Gigante C, Melotti E, Baggiano A, Mancini ME, Annoni A, Formenti A, Sakai K, Mizukami T, Pontone G, Zanotto L, Bartorelli AL, Collet C. Andreini D, et al. Among authors: trabattoni d. Radiology. 2024 Dec;313(3):e232225. doi: 10.1148/radiol.232225. Radiology. 2024. PMID: 39688482
The heart-mind relationship in women cardiovascular primary prevention: the role of depression, anxiety, distress and Type-D personality in the 10-years cardiovascular risk evaluation.
Giuliani M, Santagostino Baldi G, Capra N, Bonomi A, Marzorati C, Sebri V, Guiddi P, Montorsi P, Pravettoni G, Trabattoni D. Giuliani M, et al. Among authors: trabattoni d. Front Cardiovasc Med. 2024 Mar 7;11:1308337. doi: 10.3389/fcvm.2024.1308337. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38516002 Free PMC article.
INTRODUCTION: Cardiovascular diseases are the leading cause of death among women. Prevention programmes underscore the need to address women-specific risk factors. ...This study aimed to create "at-risk" psychological profiles for women without prior cardiovascular …
INTRODUCTION: Cardiovascular diseases are the leading cause of death among women. Prevention programmes underscore the need to addres …
Early Detection of Cardiovascular Risk Factors and Definition of Psychosocial Profile in Women Through a Systematic Approach: The Monzino Women Heart Center's Experience.
Gili S, Giuliani M, Santagostino Baldi G, Teruzzi G, Pravettoni G, Montorsi P, Trabattoni D. Gili S, et al. Among authors: trabattoni d. Front Cardiovasc Med. 2022 Mar 8;9:844563. doi: 10.3389/fcvm.2022.844563. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35345485 Free PMC article.
INTRODUCTION: Cardiovascular (CV) disease is the leading mortality cause among women, yet an alarming misrepresentation of women in CV studies and a low awareness of the impact of CV among women still persist to date. ...METHODS: Patients aged between 35 and 60 years and w …
INTRODUCTION: Cardiovascular (CV) disease is the leading mortality cause among women, yet an alarming misrepresentation of women in C …
142 results